InstalabInstalabLoading...
Instalab ResearchThe landmark FOURIER trial enrolled over 27,000 people with established heart disease who were already taking statins. Over about 2.2 years, adding Repatha reduced the combination of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, and the need for procedures to open blocked arteries from 11.3% to 9.8%. That's a 15% relative reduction.
When researchers looked specifically at the "harder" outcomes of cardiovascular death, heart attack, and stroke alone, the risk dropped from 7.4% to 5.9%, which translates to a 20% relative reduction.
This is where it gets interesting. The initial FOURIER trial was relatively short at just over 2 years. Critics wondered whether the benefits would hold up, and some worried about unknown long-term safety issues from driving cholesterol extremely low.
The answer from extension studies is encouraging. In FOURIER-OLE, researchers followed over 6,600 patients for a median of 5 additional years (with some followed for up to 8.4 years total). Those who had been randomly assigned to start Repatha earlier in the original trial had a 20% lower risk of the combined outcome of cardiovascular death, heart attack, and stroke compared to those who started later. Even more striking, they had a 23% lower risk of dying from cardiovascular causes specifically.
The relative benefit also appeared to grow during the initial trial itself. The risk reduction was 16% in the first year but increased to 25% after 12 months, suggesting that the longer you're on treatment, the more protection you get.
When Repatha drops LDL cholesterol from around 90 mg/dL down to 30 mg/dL or even lower, some people naturally wonder if that's safe. After all, cholesterol plays important roles in the body.
The research is reassuring on this point. In the long-term extension study, about 24% of patients achieved LDL levels below 20 mg/dL, and 40% were between 20 and 40 mg/dL. Researchers found a consistent pattern: lower achieved LDL levels were associated with fewer cardiovascular events, even down to levels below 20 mg/dL.
Importantly, over up to 8.6 years of follow-up, these very low levels weren't associated with increases in cancer, hemorrhagic stroke (bleeding in the brain), cognitive problems, new diabetes, or non-cardiovascular death. The overall rate of serious side effects was similar whether people took Repatha or not.
The most common side effect was mild injection-site reactions, occurring in about 2.1% of Repatha users compared to 1.6% of those on placebo. The drug didn't produce neutralizing antibodies that would make it stop working over time.
Not everyone gets the same benefit from Repatha. The research shows that your baseline risk matters enormously in determining how much you personally might gain.
People at the very highest risk see the largest absolute benefits:
In one analysis, patients with recent heart attacks saw cardiovascular events reduced by 19%, while those whose heart attacks were more remote saw an 8% reduction. Patients with multivessel coronary disease (multiple blocked arteries) had events reduced by up to 38%.
Older patients appeared to benefit as much as or more than younger patients. One analysis found that early initiation of Repatha reduced cardiovascular events by 5.4 percentage points in older patients versus 2.3 percentage points in younger patients.
People who can't tolerate statins may also benefit. In the GAUSS-2 trial, patients who experienced muscle problems on statins saw 53-56% LDL reductions with Repatha, outperforming the alternative oral medication ezetimibe by 37-39 percentage points, with fewer muscle-related side effects.
Despite encouraging results, some important questions remain.
The research hasn't definitively proven that Repatha reduces overall or cardiovascular mortality in typical secondary prevention patients over standard trial periods. A meta-analysis found clear benefits for heart attacks, strokes, and procedures, but no clear effect on mortality over approximately 2.3 years of follow-up. While the long-term extension data suggests a mortality benefit with earlier treatment, this comes from an open-label extension rather than a fully randomized comparison.
One reanalysis of regulatory data raised questions about cardiovascular mortality trends in the original FOURIER trial, noting a non-significant 20% higher rate of cardiovascular deaths in the evolocumab group with different death adjudication. This remains a minority view, but it underscores that mortality effects aren't yet settled.
We also have less than 10 years of hard outcome data. Heart disease develops over decades, so the true lifetime benefit remains uncertain.
For people with established atherosclerotic heart disease who remain above their LDL goals despite maximum statin therapy, Repatha offers a meaningful additional layer of protection against heart attacks, strokes, and procedures. The benefits appear to grow over time and remain safe even when cholesterol drops to very low levels.
The people most likely to benefit are those at the highest baseline risk: recent heart attack survivors, those with multiple blocked arteries, peripheral artery disease, or additional high-risk conditions like diabetes. For these patients, the absolute number of events prevented will be larger, making the trade-offs more favorable.
The drug requires injections every two weeks or monthly, which is a consideration but one that many patients manage well. If you're in a high-risk category and your LDL remains elevated despite statins, this is a conversation worth having with your doctor.